Joseph J. Sarret, M.D., J.D.

Joseph J. Sarret, M.D., J.D.

Chief Executive Officer and Director

Joseph J. Sarret joined CohBar as Chief Executive Officer and Director in May 2021.  From 2019 until 2021, Dr. Sarret worked as a consultant in the life science industry, focusing on business development and corporate development activities.  From 2015 until 2019, he served as Chief Business Officer at Corium International, Inc. (formerly NASDAQ: CORI), a biopharmaceutical company developing and commercializing transdermal healthcare products.  Prior to Corium, Dr. Sarret served in senior leadership roles at Solazyme, Inc. (formerly NASDAQ: SZYM) and Sevident, Inc.  From 2005 to 2012, he held several executive management roles, most recently serving as Chief Business Officer at Codexis, Inc. (NASDAQ: CDXS), a publicly traded life sciences company developing novel enzymes for a variety of applications.  Earlier in his career, Dr. Sarret worked as a practicing clinician focused on patients with human immunodeficiency virus and an attorney specializing in IP transactional work in the life sciences industry.  He received a B.A. in human biology from Stanford University, an M.D. from the University of California, San Francisco School of Medicine and a J.D. from Stanford Law School.

Jeffrey F. Biunno, CPA, MBA

Jeffrey F. Biunno, CPA, MBA

Chief Financial Officer, Secretary and Treasurer

Jeffrey F. Biunno joined our Company in October 2013 as chief financial officer and was appointed secretary and treasurer in September 2014. Prior to joining CohBar, Mr. Biunno served as chief financial officer, secretary and treasurer of ManageIQ, Inc., a provider of global cloud IT systems management solutions, from March 2012 until its acquisition by Red Hat, Inc. in December 2012. From February 2009 until March 2012 Mr. Biunno served as vice president and worldwide controller of Dialogic Inc., a provider of mobile telecommunications network software and hardware enterprise solutions then listed on NASDAQ. Mr. Biunno founded Scalable Financial Solutions, LLC, a financial consulting firm, and operated it from March 2008 to January 2009. From February 2005 to March 2008, Mr. Biunno worked at Geller & Company, a financial services consulting firm. From 1997 to 2004, Mr. Biunno served as vice president and corporate controller of Novadigm, Inc. (NASDAQ: NVDM), an international provider of IT systems management solutions to Fortune 500 companies and government agencies. Mr. Biunno received a B.S. in accounting and an MBA in finance from Montclair State University. Mr. Biunno is a certified public accountant.

Kent Grindstaff, Ph.D

Kent Grindstaff, Ph.D

Senior Vice President of Research

Dr. Kent Grindstaff rejoined CohBar in January 2022. Dr. Grindstaff was previously at BioAge Labs, where he was the Senior Vice President, Discovery Research. Prior to BioAge Labs, he served for six years as the VP, Biology at CohBar. Earlier in his career, Dr. Grindstaff was Vice President, Global Operations at Solvo Biotechnology and Principal Investigator at XenoPort, Inc. Dr. Grindstaff holds a B.A. in Biology from Knox College, received his Ph.D. in Molecular Cell Biology and Biochemistry from Washington University in St. Louis and completed his post-doctoral fellowship in the Department of Molecular and Cellular Physiology at Stanford University.

Nick Vlahakis, M.D.

Nick Vlahakis, M.D.

Acting Chief Medical Officer

Dr. Vlahakis joined our company as Acting Chief Medical Officer in 2022 and is responsible for the clinical development of CohBar’s portfolio of therapeutic candidates. Prior to joining CohBar, Nick was Vice President and Head of Clinical Development at Global Blood Therapeutics Inc. (GBT), where he advanced voxeletor (Oxbryta) to approval in sickle cell disease. Whilst at GBT, he also was the product development lead for the development of voxeletor for patients with IPF. Prior to GBT, Nick served as the VP and Head of the Respiratory Disease Area at Unity Biotechnology, developing clinical strategy for pre-clinical assets across a broad range of respiratory diseases, including IPF. Nick began his Industry career at Genentech, serving as clinical lead for products in early and late clinical development across a diverse group of disease area indications. Prior to entering industry, Nick was on the faculty at Mayo Clinic in the Division of Pulmonary & Critical Care, where he provided clinical care to patients with respiratory diseases and critical illness. He also had an NIH-funded lab studying the biology of fibrosis, acute lung injury and angiogenesis and has published more than 60 peer-reviewed articles. Nick received his M.B.B.S medical degree at the University of Adelaide in Australia and completed his Internal Medicine residency and Pulmonary Fellowship at the Mayo Clinic.